Ramucirumab
Cyramza (ramucirumab) is an antibody pharmaceutical. Ramucirumab was first approved as Cyramza on 2014-04-21. It is used to treat colorectal neoplasms, non-small-cell lung carcinoma, and stomach neoplasms in the USA. It has been approved in Europe to treat stomach neoplasms. The pharmaceutical is active against vascular endothelial growth factor receptor 2.
| Trade Name | Cyramza |
|---|---|
| Common Name | Ramucirumab |
| Indication | colorectal neoplasms, non-small-cell lung carcinoma, stomach neoplasms |
| Drug Class | Monoclonal antibodies |
